8 results about "Oculopathy" patented technology

The invention provides a method of treating or reducing the severity of thyroid-associated ophthalmopathy (TAO), also known as thyroid eye disease (TED) or Graves' ophthalmopathy or orbitopathy (GO), or a symptom or aspect thereof, in subjects that have undergone prior treatment for TAO, TED, or GO, and either did not respond to said prior treatment or relapsed after said prior treatment. The invention also provides antibodies, or antigen binding fragments thereof, and pharmaceutical compositions useful in the disclosed methods.

Provided herein are methods of treating or reducing the severity of thyroid eye disease (TED), also known as thyroid-associated ophthalmopathy (TAO), or Graves' ophthalmopathy or orbitopathy (GO), as well as antibodies, or antigen binding fragments thereof, and pharmaceutical compositions comprising them, useful in the methods.

The application belongs to the technical field of biological medicine, and relates to a construction method of a thyroid-associated ophthalmopathy animal model, which comprises the following steps: after a pseudo-sterile animal model is constructed, fecal bacteria liquid of a mild patient with thyroid-associated ophthalmopathy is first administered to the pseudo-sterile animal model in a first stage, and Ad-TSHR is injected once in the second half of the first stage; then fecal bacteria liquid of a moderate patient with thyroid-associated ophthalmopathy is administered to the pseudo-sterile animal model in a second stage, and Ad-TSHR is injected once in the second half of the second stage; then fecal bacteria liquid of a severe patient with thyroid-associated ophthalmopathy is administered to the pseudo-sterile animal model in a third stage, and Ad-TSHR is injected once in the second half of the third stage; finally, Ad-TSHR is injected once in the second half of a fourth stage; and thus the thyroid-associated ophthalmopathy animal model is obtained. The model has a high incidence of 80% and a significantly reduced mortality rate under the condition of less immunization times.

The invention discloses a positive ion metabolism marker for thyroid-associated ophthalmopathy, a product and application of the positive ion metabolism marker. The positive ion marker is prepared from any one or more of L-arginine-L-valeryl-L-lysine, cholesterol beta-epoxide, phosphatidylcholine (18: 4 / 20: 5), sphingosine galactoside and oestrone. The invention provides a kit which comprises a detection reagent for detecting the positive ion marker. A computer program product associated with thyroid-related ocular diseases is provided. The product provided by the invention has good feasibility and accuracy, can effectively evaluate the risk of thyroid-related eye diseases, and provides a new tool for clinical diagnosis.

The present application relates to a kind of deep learning method based on SPECT / CT detection thyroid-related eye disease activity, including two stages of eye muscle segmentation stage and activity staging classification, in the eye muscle segmentation stage, first, the CT image of eye is three-dimensional reconstruction, and training eye muscle semantic segmentation model, finally using the eye muscle segmentation model of well-trained in test set eye muscle mask;In the classification stage of judging whether thyroid-related eye disease is in active period, three-channel data are formed by using eye muscle mask, SPECT and CT image, and three-channel data are used to train classification model, SPECT / CT image and the eye muscle mask of patient are combined into three-channel image and input into classification model, and finally the activity of thyroid-related eye disease is output by the trained classification model.Through the deep learning method of two stages, the activity of thyroid-related eye disease is automatically classified.

The present invention provides a TSHR antagonist compound of formula (I), a pharmaceutical composition, a method for preparing same, and use thereof. The compound has a good TSHR antagonistic effect and is used for treating thyroid-related disorders and / or diseases, such as hyperthyroidism, Graves' disease, Graves' ophthalmopathy, and thyroid-associated ophthalmopathy, and for preparing a medicament for such disorders or diseases.

The application discloses a negative ion metabolic marker of thyroid-associated ophthalmopathy, a product and application thereof. The metabolic marker comprises any one or several of 7alpha, 17alpha-dimethyl-5beta-androstane-3alpha, 17beta-diol, N, N-dimethylphosphatidyl ethanolamine, 15(S)-hydroxyeicosatrienoic acid and 1-tetradecanoyl-2-[(9Z)-octadecenoyl]-sn-glycero-3-phosphatidylcholine. The application provides a kit comprising detection reagents for detecting the negative ion metabolic marker. The application provides a computer program product for thyroid-associated ophthalmopathy. The product provided by the application has good feasibility and accuracy, can effectively evaluate the risk of thyroid-associated ophthalmopathy, and provides a new tool for clinical diagnosis.

Disclosed herein are compounds useful for the inhibition of insulin-like growth factor 1 receptor (IGF-1R). The compounds have a general Formula (I): or pharmaceutically acceptable salts thereof, wherein the variables of Formula (I) are as defined herein. Also provided herein are pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, thyroid-associated ophthalmopathy, Graves' opthalmopathy or Graves' orbitopathy. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula (I).